MaaT Pharma Advances MaaT034 for Clinical Trials in Solid Tumors

MaaT Pharma has announced a scheduled Pre-IND meeting with the FDA in October 2026, marking a key regulatory step for MaaT034. The focus will be on Chemistry, Manufacturing, and Controls as the company pursues clinical development. MaaT034 is a first-in-human study designed to assess optimal dosing and pre-treatment regimens for solid tumors, including non-small cell lung cancer and advanced melanoma, using PD-(L)1 inhibitors.

Set to potentially initiate in late 2027, the study aims to restore anti-tumor immunity through microbiome modulation, potentially overcoming resistance to current treatments. MaaT034, deriving from the MET-C platform, represents an innovative microbial ecosystem designed to enhance treatment outcomes in oncology.

The company continues to seek funding and strategic partnerships to support this endeavor, highlighting its commitment to addressing unmet medical needs in cancer treatment.